Like the people who worry about the spike protein in the vaccines, but still don't realise that the virus contains exactly that protein and many more reasons to worry.
For me, covidiots are the people who keep taking booster shot 5, 7, 15, 25 and so on, and then go "yeah I got very sick but if I didn't take the vaccine, I would have been much sicker" :)
The vaccine results are clear. You are much, much less likely to have a severe health outcome if you are vaccinated, even with omicron. The vast majority of the people hospitalized with omicron and overwhelming hospitals right now are unvaccinated people. For people vaccinated and boosted, omicron is significantly milder.
But that posting's a pretty good example of what I mean by covidiot.
peekaboo knows that noone's taken booster shot 5, let alone 25, so noone with five doses could possibly have gotten very sick and said anything at all. He's just making five doses sound ridiculous. He has no rational argument.
He could have a rational opinion — a vaccine against an older disease is often given in five doses or even more, and he could have a general, well-reasoned opinion about vaccine doses. (Google for "during childhood, five doses are recommended, with a sixth given during adolescence" if you want to read about that.)
AFAICT peekaboo hasn't ever suggested that the vaccine for that disease is idiotic, and he also hasn't suggested reasons why why covid should require fewer doses than that disease. He just makes stuff up, and that's a fine example of what I meant by "covidiot". (peekaboo: If you have posted any of that, perhaps elsewhere on the web, please do post links and I'll apologise.)
India had vaccine manufacturing already, with over a billion doses of locally produced covid vaccines dispensed and much more than that produced. Clearly the patents and pricing weren't debilitating problems.
“India never should have been in this position. The government is currently engaged in international disputes over vaccine waivers and intellectual property rights, while a horrific and record-setting surge of COVID-19 cases continues to devastate its population. The country’s recent vaccine policies — opening vaccination for all above the age of 18 while reeling under severe shortage…”
Even if India never should have been in this position, the cost of its being in this position seems manageable. By way of comparison, India spends 6-7 times as much money on its air force as on buying corona vaccines. This isn't a large budget item, not a large problem.
There were shortages, but AFAICT those weren't related either to pricing or to patents. The government ordered what it thought necessary, the manufacturer set up production to match that and delivered doses as ordered. Then more was needed and scaling up further took time.
Overall, I can't see reason to count the three problems in the headline as big problems for India.
Great effectiveness, easy for any Hep B manufacturer to make, easier storage requirements, and patent-free.
> Texas Children’s hospital said the vaccine was over 90% effective against the original Covid-19 strain and over 80% effective against the Delta variant. The vaccine’s efficacy against the Omicron variant is currently being tested.
> “We make the protein, directly and synthetically, in the lab using the yeast system,” Bottazzi explained. “We ask the yeast to make a protein that looks just like a protein that is made by the virus. Then we immunize the protein and the body then processes this protein and presents it to the immune system. Therefore, you don’t ask your body to do any major manipulation of the coding.”
> Crucially, storing the Corbevax vaccine only requires standard refrigeration, unlike the Pfizer vaccine, which requires ultra-cold storage in transit.
> Biological E, an Indian pharmaceutical company accustomed to producing hepatitis B vaccines with whom Bottazzi’s team has a longstanding relationship, has already produced 150m doses of the new Corbevax vaccine and will soon be able to produce 100m doses every month.
12 comments
[ 3.4 ms ] story [ 34.8 ms ] threadRobustness against future strands and acceptability to covidiots are the two big problems where I live, at least as far as I can see.
Like the people who worry about the spike protein in the vaccines, but still don't realise that the virus contains exactly that protein and many more reasons to worry.
peekaboo knows that noone's taken booster shot 5, let alone 25, so noone with five doses could possibly have gotten very sick and said anything at all. He's just making five doses sound ridiculous. He has no rational argument.
He could have a rational opinion — a vaccine against an older disease is often given in five doses or even more, and he could have a general, well-reasoned opinion about vaccine doses. (Google for "during childhood, five doses are recommended, with a sixth given during adolescence" if you want to read about that.)
AFAICT peekaboo hasn't ever suggested that the vaccine for that disease is idiotic, and he also hasn't suggested reasons why why covid should require fewer doses than that disease. He just makes stuff up, and that's a fine example of what I meant by "covidiot". (peekaboo: If you have posted any of that, perhaps elsewhere on the web, please do post links and I'll apologise.)
The article already mentions an Indian manufacturer getting up to speed with this vaccine, with 150 million doses already manufactured.
If you search for “lack of covid vaccines in Africa” there are many, many results.
I’m tempted to say you’ve asked the question with a very Western mindset, not really considering less developed nations.
India had vaccine manufacturing already, with over a billion doses of locally produced covid vaccines dispensed and much more than that produced. Clearly the patents and pricing weren't debilitating problems.
May 17th, 2021
https://www.theverge.com/2021/5/17/22440292/vaccine-waivers-...
There were shortages, but AFAICT those weren't related either to pricing or to patents. The government ordered what it thought necessary, the manufacturer set up production to match that and delivered doses as ordered. Then more was needed and scaling up further took time.
Overall, I can't see reason to count the three problems in the headline as big problems for India.
Great effectiveness, easy for any Hep B manufacturer to make, easier storage requirements, and patent-free.
> Texas Children’s hospital said the vaccine was over 90% effective against the original Covid-19 strain and over 80% effective against the Delta variant. The vaccine’s efficacy against the Omicron variant is currently being tested.
> “We make the protein, directly and synthetically, in the lab using the yeast system,” Bottazzi explained. “We ask the yeast to make a protein that looks just like a protein that is made by the virus. Then we immunize the protein and the body then processes this protein and presents it to the immune system. Therefore, you don’t ask your body to do any major manipulation of the coding.”
> Crucially, storing the Corbevax vaccine only requires standard refrigeration, unlike the Pfizer vaccine, which requires ultra-cold storage in transit.
> Biological E, an Indian pharmaceutical company accustomed to producing hepatitis B vaccines with whom Bottazzi’s team has a longstanding relationship, has already produced 150m doses of the new Corbevax vaccine and will soon be able to produce 100m doses every month.